presumed ocular histoplasmosis

pre·sumed oc·u·lar his·to·plas·mo·sis

subretinal neovascularization in the macular region associated with chorioretinal atrophy and pigment proliferation adjacent to the optic disc, and peripheral chorioretinal atrophy ("histo-spots").

pre·sumed oc·u·lar his·to·plas·mo·sis

(prē-zūmd' ok'yū-lăr his'tō-plaz-mō'sis)
Subretinal neovascularization in the macular region associated with chorioretinal atrophy and pigment proliferation adjacent to the optic disc, and peripheral chorioretinal atrophy ("histo-spots"); presumed secondary to infection by Histoplasma capsulatum.
References in periodicals archive ?
share the case of a myopic patient with persistent juxtafoveal CNV secondary to presumed ocular histoplasmosis who was treated with a total of 5 ranibizumab injections during 1.
Presumed Ocular Histoplasmosis Syndrome (POHS) is a syndrome characterised by multiple scars in the choroid (Histo spots), neovascularization, peripapillary atrophy with a clear vitreous and aqueous.
Association of the HLA-DR15/HLA-DQ6 haplotype with development of choroidal neovascular lesion in presumed ocular histoplasmosis syndrome.
They may be large, solitary lesions, such as those seen following Toxoplasma infection, but sometimes they result in a "spotty" fundus appearance as seen in the presumed ocular histoplasmosis syndrome (POHS), birdshot chorioretinitis, multifocal choroiditis and pusctete inner choroidopathy (PIC).
Which of the following statements about Presumed Ocular Histoplasmosis Syndrome (POHS) is TRUE?
gondii chorioretinitis may resemble the posterior uveitis of tuberculosis, syphilis, leprosy, or presumed ocular histoplasmosis syndrome .
Nasdaq: QLTI; Toronto) has announced that the FDA has approved Visudyne(TM) (verteporfin for injection) therapy for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to pathologic myopia (severe near-sightedness) and presumed ocular histoplasmosis.
Dan Myers, president of Novartis Ophthalmics, North America said, "The fact that Visudyne therapy has demonstrated the ability to stabilize and in some cases improve vision in these pathologic myopia and presumed ocular histoplasmosis patients is another remarkable success story for this breakthrough therapy.
The current market drugs include Lucentis (ranibizumab), approved for CNV associated with wet age-related macular degeneration (AMD), Visudyne (verteporfin), approved for CNV associated with wet AMD, presumed ocular histoplasmosis and pathologic myopia, and Macugen (pegaptanib), approved for CNV associated with wet AMD.
Presumed ocular histoplasmosis syndrome (POHS) is a clinical entity that is characterized by small, round, discrete, macular or mid peripheral atrophic (punched out) chorioretinal lesions (histo spots), peripapillary scarring, choroidal neovascularization (CNV), and the absence of anterior uveitis and vitritis.
Presumed ocular histoplasmosis syndrome (POHS) was first described in 1959 by Woods and Wahlen (1) as peripheral chorioretinal scar and hemorrhagic macular disciform lesion in a patient with positive histoplasmin skin test.
These cases were diagnosed with myopia, punctate inner choroidopathy (PIC), presumed ocular histoplasmosis syndrome (POHS) and idiopathic CNV (37,38,39)